Published in Arch Intern Med on June 22, 2009
Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis (2012) 1.69
Health-related quality of life outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens (2010) 1.21
Physical and psychological burden of chronic kidney disease among older adults. Am J Nephrol (2010) 0.90
Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol (2011) 0.90
The new FDA labeling for ESA--implications for patients and providers. Clin J Am Soc Nephrol (2012) 0.88
Assessing and improving the health-related quality of life of patients with ESRD. Nat Rev Nephrol (2012) 0.88
Standardised outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. Trials (2015) 0.85
Transfusion of red cells in hematopoietic stem cell transplantation (TRIST): study protocol for a randomized controlled trial. Trials (2011) 0.83
The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients. Int J Nephrol Renovasc Dis (2016) 0.79
Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia. Int J Mol Sci (2015) 0.79
Treating anemia with erythropoiesis-stimulating agents: effects on quality of life. Arch Intern Med (2009) 0.79
Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis. Clinics (Sao Paulo) (2014) 0.75
Appropriateness of anemia management in hemodialysis patients. Saudi Pharm J (2011) 0.75
Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial. PLoS One (2017) 0.75
Falls in nursing home residents receiving pharmacotherapy for anemia. Clin Interv Aging (2012) 0.75
Differences in quality of life of hemodialysis patients between dialysis centers. Qual Life Res (2011) 0.75
Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study. PLoS One (2017) 0.75
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03
US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care (2005) 9.89
Relation between kidney function, proteinuria, and adverse outcomes. JAMA (2010) 8.26
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 7.99
A meta-analysis of the association between adherence to drug therapy and mortality. BMJ (2006) 7.79
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46
Age and association of kidney measures with mortality and end-stage renal disease. JAMA (2012) 7.20
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA (2012) 6.26
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int (2011) 6.21
Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet (2012) 5.65
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA (2007) 5.31
The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension (2011) 5.14
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet (2012) 5.10
Cardiovascular disease in kidney donors: matched cohort study. BMJ (2012) 5.00
Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med (2006) 4.90
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care (2005) 4.78
Recommendations on screening for breast cancer in average-risk women aged 40-74 years. CMAJ (2011) 4.68
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis (2010) 4.28
Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet (2012) 4.25
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ (2007) 3.95
Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med (2017) 3.90
When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase. Kidney Int (2009) 3.70
The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist. Control Clin Trials (2002) 3.62
Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 3.62
Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem (2003) 3.61
Adapting the Charlson Comorbidity Index for use in patients with ESRD. Am J Kidney Dis (2003) 3.60
Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation (2004) 3.56
Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci (2003) 3.54
Recommendations on screening for type 2 diabetes in adults. CMAJ (2012) 3.51
Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med (2011) 3.49
Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Med Care (2005) 3.46
Physical activity level and health-related quality of life in the general adult population: a systematic review. Prev Med (2007) 3.45
Recommendations on screening for cervical cancer. CMAJ (2013) 3.32
Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. Arch Intern Med (2012) 3.26
Early recognition and prevention of chronic kidney disease. Lancet (2010) 3.19
Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med (2011) 3.13
Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA (2009) 3.11
Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation (2005) 3.10
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA (2011) 3.08
Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. Arch Intern Med (2007) 3.06
Change in the estimated glomerular filtration rate over time and risk of all-cause mortality. Kidney Int (2013) 3.05
A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int (2005) 3.03
Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med (2010) 2.97
Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet (2010) 2.95
Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. Kidney Int (2008) 2.88
Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol (2006) 2.84
An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol (2004) 2.74
Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther (2007) 2.71
Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin. CMAJ (2009) 2.70
Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS (2010) 2.62
Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. JAMA (2010) 2.61
Nrf2, a multi-organ protector? FASEB J (2005) 2.61
Differential gene expression patterns revealed by oligonucleotide versus long cDNA arrays. Toxicol Sci (2002) 2.61
Overview of the Alberta Kidney Disease Network. BMC Nephrol (2009) 2.58
An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods. J Clin Epidemiol (2004) 2.58
Nocturnal hemodialysis does not improve overall measures of quality of life compared to conventional hemodialysis. Kidney Int (2008) 2.56
Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ (2004) 2.55
Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci U S A (2009) 2.54
Guidelines for the management of chronic kidney disease. CMAJ (2008) 2.54
A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med (2002) 2.49
The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal (2009) 2.49
Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med (2011) 2.48
A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med (2004) 2.48
Rates of treated and untreated kidney failure in older vs younger adults. JAMA (2012) 2.43
The direct and indirect economic costs incurred by living kidney donors-a systematic review. Nephrol Dial Transplant (2006) 2.41
Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ (2011) 2.40
Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2007) 2.38
Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int (2004) 2.37
Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol (2013) 2.34
Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci (2008) 2.34
NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J Biol Chem (2003) 2.33
Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care (2012) 2.32
The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol (2004) 2.32
Weekend hospital admission, acute kidney injury, and mortality. J Am Soc Nephrol (2010) 2.30
A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int (2004) 2.29
Access to kidney transplantation among remote- and rural-dwelling patients with kidney failure in the United States. JAMA (2009) 2.26
Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA (2008) 2.22